CTCX vs. LUCD, DXR, DRIO, NSPR, XAIR, CODX, LNSR, CTSO, APYX, and MODD
Should you be buying Carmell stock or one of its competitors? The main competitors of Carmell include Lucid Diagnostics (LUCD), Daxor (DXR), DarioHealth (DRIO), InspireMD (NSPR), Beyond Air (XAIR), Co-Diagnostics (CODX), LENSAR (LNSR), Cytosorbents (CTSO), Apyx Medical (APYX), and Modular Medical (MODD). These companies are all part of the "surgical & medical instruments" industry.
Lucid Diagnostics (NASDAQ:LUCD) and Carmell (NASDAQ:CTCX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, valuation, profitability, dividends, risk, media sentiment and institutional ownership.
74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 24.2% of Carmell shares are held by institutional investors. 4.8% of Lucid Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Carmell has lower revenue, but higher earnings than Lucid Diagnostics.
Lucid Diagnostics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Carmell has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500.
Lucid Diagnostics received 26 more outperform votes than Carmell when rated by MarketBeat users.
Lucid Diagnostics currently has a consensus price target of $2.75, indicating a potential upside of 196.11%. Given Carmell's higher possible upside, equities analysts clearly believe Lucid Diagnostics is more favorable than Carmell.
Carmell has a net margin of 0.00% compared to Carmell's net margin of -2,169.07%. Lucid Diagnostics' return on equity of -154.49% beat Carmell's return on equity.
In the previous week, Lucid Diagnostics had 9 more articles in the media than Carmell. MarketBeat recorded 12 mentions for Lucid Diagnostics and 3 mentions for Carmell. Lucid Diagnostics' average media sentiment score of 0.92 beat Carmell's score of 0.01 indicating that Carmell is being referred to more favorably in the news media.
Summary
Lucid Diagnostics beats Carmell on 8 of the 13 factors compared between the two stocks.
Get Carmell News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTCX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
